Article info
PDFResearch ethics
Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson’s disease and proposed criteria for use of sham surgery controls
- Correspondence to: Dr R L Albin, Department of Neurology, University of Michigan, 4412D Kresge III, 200 Zina Pitcher Place, Ann Arbor, MI, 48109–0585, USA; ralbin{at}umich.edu
Citation
Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson’s disease and proposed criteria for use of sham surgery controls
Publication history
- Accepted March 4, 2002
- Revised February 28, 2002
- First published October 1, 2002.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2002 by the Journal of Medical Ethics
Other content recommended for you
- Sham surgery controls are mitigated trolleys
- Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable?
- Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease
- Unilateral pallidotomy for Parkinson’s disease: results after more than 1 year
- Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study
- Finnish Degenerative Meniscal Lesion Study (FIDELITY): a protocol for a randomised, placebo surgery controlled trial on the efficacy of arthroscopic partial meniscectomy for patients with degenerative meniscus injury with a novel ‘RCT within-a-cohort’ study design
- Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease
- Sham surgery can be ethical and safe
- Comparison of patient rated treatment response with measured improvement in Parkinson's disease
- Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study